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FIBROBLAST migration,  proliferation,  extacellular
matrix protein synthesis and degradation are the key
events  in  various  biological  and  pathological  pro-
cesses  in  pulmonary  fibrosis.  In  addition,  biopsy
specimens  from  the  lungs  of  patients  with  plu-
momary  fibrosis  show  increased  numbers  of  mast
cells which have metachromatic granules containing
heparin,  histamin  and  proteases.  Little  is  known
about how these products influence pulmonary fibro-
sis. In the present study, we investigated the effect of
heparin  and  related  glycosaminoglycans  on  PDGF-
induced lung fibroblast proliferation and chemotactic
response in vitro. In addition, we examined the effect
of heparin on both the induction of matorix metal-
loproteinases  (MMPs)  and  MMPs  activity  in  lung
fibroblasts in vitro.
Heparin, de-N-sulphated heparin but not heparan
sulphate inhibited PDGF-induced lung fibroblast pro-
liferation. In contrast, only heparin inhibited PDGF-
stimulated  human  lung  fibroblast  chemotaxis.  Neg-
atively  charged  poly-L-gultamic  acid  had  no  effect
on  either  fibroblast  proliferation  or  chemotaxis.
Thus the negative charge  alone  cannot  account  for
the ant-proliferative  and  anti-chemotactic effects  of
heparin.
Furthermore,  heparin  and heparan  sulphate  also
had  no  inhibitory  effect  on  induction  of  MMPs,
including  MMP-1  (interstitial  collagenase),  MMP-2
(gelatinase A) and MMP-9 (gelatinase B). Only heparin
inhibited  both  MMP-1  and  MMP-2/MMP-9  activity.
Additionally,  tissue  inhibitor  of  metalloproteinase
type 1 (TIMP-1) and type 2 (TIMP-2) inhibited PDGF-
stimulated  human  lung  fibroblast  chemotaxis.  The
ability  of  heparin  to  inhibit  fibroblast  chemotaxis
may account for the inhibitory effect of heparin on
MMP activity.
The  above  results  suggested  that  heparin  and
related  glycosaminoglycans  differentially  regulate
PDGF-induced  lung  fibroblast  proliferation,  chem-
otaxis and MMPs activity and further that these effects
may have a key role in extracellular matrix remodel-
ing in inflammatory lung disease.
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Introduction
Biopsy  specimens  from  the  lungs  of  patients  with
plumonary fibrosis show increased numbers of mast
cells1–3 which have metachromatic granules contain-
ing heparin, histamine and proteases. Morphological
studies also suggested fibroblast proliferation, exces-
sive synthesis and deposition of collagen and other
extracellular matrix proteins4,5 in pulmonary fibrosis.
However,  less  is  known  about  the  interaction  of
fibroblasts,  growth  factors  and  extracellular  matrix
molecules in inflammation.
Platelet-derived  growth  factor  (PDGF),  which  is
one  of  the  most  important  mitogens  derived  from
various  cells  including  alveolar  macrophages  and
platelets,  may  implicate  the  extracellular  matrix
proteins  and  matrix  metalloproteinases  (MMPs)6 in
wound  healing. The  role  of  PDGF  in  inflammatory
lung  diseases  is  consistent  with  the  observation  of
PDGF-like  proteins  localised  to  macrophages  and
epithelial  cells  associated  with  tissue  repair  of
patients with idiopathic pulmonary fibrosis.7,8
Mast-cell  mediators  may  act  as  growth  factors,
including histamine and tryptase, to fibroblasts. Hep-
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matrix and well known polyanionic anticoagulant, is
now recognised as an anti-inflammatory agent. Hep-
arin  and  heparin  related  glycosaminoglycans  have
numerous other functions, among which are inhibi-
tion  of  fibrin  deposition  in  tissues,9 inhibition  of
fibroblast proliferation associated with proteases10,11
and  inhibition  of  allergen-induced  recruitment  of
eosinophils into the airway.12 –14 Heparin and heparan
sulphate,  which  is  one  of  the  main  extracellular
matrix  components,  also  inhibit  vascular  smooth
muscle cell division.15,16 This action may indicate that
heparin  and  related  glycosaminoglycans  play  an
important role in modulation not only of airway wall
remodelling  in  asthma17,18 but  also  of  extracellular
matrix remodeling in pulmonary fibrosis.
MMPs  are  major  proteolytic  enzymes  involved  in
degrading  and  remodeling  the  extracellular  matrix.
The matrix metalloproteinase-1 (MMP-1) derived from
fibroblasts is interstitial collagenase known to degrade
collagen  types  I,  II,  III  and  others.19 The  type  IV
collagenase (MMP-2 and MMP-9), which is now found
in  fibroblasts  and  macrophages  has  the  ability  to
degrade a wide range of extracellular matrix proteins,
including  basement  membrane  collagen  type  IV ,
fibronectin  and  gelatin.20,21 Recently,  it  has  been
suggested  that  MMPs  including  MMP-2,  MMP-3  and
MMP-9  play  a  major  role  in  the  degradation  of  the
extracellular matrix during tumor cell invasion.17,18 In
pulmonary fibrosis, MMPs are regulated by numerous
factors  including  growth  factors  and  inflammatory
mediators  may  play  a  key  role  in  modulating  lung
tissue injury and extracellular matrix remodeling.
Therefore, in the present study we investigate the
possible influence of heparin and glycosaminoglycan
on PDGF-induced human lung fibroblast proliferation,
chemotaxis and MMPs activity.
Material and methods
Materials
Recombinant  human PDGF-BB  was purchased  from
Genzyme  (USA).  Heparin  (porcine),  whose  activity
was  1000  units  per ml,  was  purchased  from  Novo
Nordlisk  (Denmark).  Heparan  sulphate  (bovine
mucosa), de-N-sulphated heparin and poly-L-gultamic
acid were obtained from Sigma (USA). Anti-hMMP1,
anti-hMMP2  and  anti-hMMP9  were  purchased  from
Fuji Chemi Co. (Japan), as were recombinant hTIMP-1
and  hTIMP-2.  Tissue  culture  plates  were  obtained
from Sumitomo Bakelite (Japan) and transwell culture
dishes were from Corning Coster (USA).
Cell culture, proliferation and adhesion
Human  lung  fibroblasts  CCL-153  obtained  from the
American Type Culture Collection (ATCC) were cul-
tured in a cell culture flask, in modified Ham’s F12
(Sigma) supplemented with 10% FCS  at  37°C in  an
atomosphere of 5% CO2. The cells were plated at 1.0
´ 105 cells in a 24-well plate in media with 10% FCS
for  72 h  then  washed  three  times  in  F12,  and
synchronized with serum free F12 for 48 h. Cells were
incubated with heparin (0.1–100 U/ml), heparan sul-
phate,  de-N-sulphated  heparin  and  poly-L-gultamic
acid (0.1–100 g/ml) with serum free media for 24 h.
Cells were removed from plates with PBS and EDTA,
replaced and suspended in a microtest tube with 1 ml
of  F12  media. Cell counts and viability  were deter-
mined by trypan blue exclusion (GIBCO) and counted
in a hemocytometer.
[H
3]-Thymidine incorporation assay
Lung fibroblasts were plated at 1.0 ´ 105 cells in  a
24-well plate in media with 10% FCS until confluence.
Cells were washed three times in F12, and incubated
in  serum-free F12  medium with compounds pulsed
with [H3]-thymidine (0.04 m Ci/ml). Incorporation of
[H3]-thymidine was measured after 24 h by detaching
the cells with trypsin solution, harvesting the cells on
filters  using  the Tiltertek  cell  harvester  and  under-
going lysis with distilled water. Radioactivity on the
filters  was  determined  by  scintillation  counting  of
dpm/well.
Chemotaxis assay
Chemotaxis  stimulated  by  PDGF  (10 m g/ml)  was
measured  using  the  modified  Boyden  chamber  as
described previously.22 The test  compounds  diluted
with Ham’s F12 medium were placed lower in wells
in the lower chamber. The wells were covered with a
collagen  (type  I  and  type  III)-coated  polycarbonate
filter.  Human  lung  fibloblasts  5  ´ 104 cells  and
medium  were  added  to  the  wells  in  the  upper
chamber.  Anti-hMMP1,  anti-hMMP2,  anti-hMMP9,
recombinant hTIMP-1 and hTIMP-2 were added to the
wells  in  the  upper  chamber  for  the  chemotactic
inhibition  assay.  After  8 h  incubation  at  37°C  in
5%CO2, the filters were removed and cells were fixed
and  stained  using  Diff-Quik  stain. The  chemotactic
response was determined by counting the number of
cells/microscopic field on the lower surface.
Matrix metalloproteinases assay
An  assay  to  determine  matrix  metalloproteinases
(MMPs)  activity  was  measured  by  the  diffuse  fibril
method based on that of Cawston and Barrett. This
method utilizes FITC labeled type I collagen (human)
(MMP-1 activity) or type IV collagen (bovine) (MMP-
2/MMP-9 activity) which was affected by collagenases
incubated  at  37°C  or  at  42°C  to  produce  soluble
fragments that can be separated from intact fibrils by
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activity is defined as the amount of enzyme degrading
1 m g  of  collagen  per  minute  at  37  or  42°C.  The
specificity of the assay was confirmed by identifica-
tion  of  MMPs  reaction  products  using  an  immuno-
fluoresence  electrophotometer  as  described
previously.23
Reverse transcription polymerase chain
reaction amplification (RT-PCR)
Total RNA was extracted from fibroblasts by RNAzol().
First-strand cDNA was prepared from 3 m g total RNA
in 30 m l reaction volume, 50 mM Tris (pH 8.3), 75 mM
KCl, 3 mM MgCl2, 10 mM DTT, 1 mM dNTPs, 40 U
RNAse inhibitor and 200 U reverse transcriptase.
Oligonucleotide  primers  for PCR  amplification  of
MMP-1, MMP-2 and MMP-9 were designed according
to published sequences for MMP-1, MMP-2 and MMP-
9. Primers  used were as follows: MMP-1: 59 AAGGT-
TAGCTTACTGTCACACGCTT,39 AGAACGAGAACACA-
AAGATCTCAGC;  MMP-2:  59 CTTTGCAGGAGACAA-
GTTCTGG,39 TTAAGGTGGTGCAGGTATCTGC;  and
MMP-9:  59 CCATGAGTCCCTGGCAG,39 TCCCCCTG-
CCCTCAGAGAA.
Amplification was performed in a final volume of
25 m 1 with 10 mM Tris (pH8.3), 50 mM KCl, 1.5 mM
MgCl2, 1.25 mM dNTPs, 7.5 pmol of each primer and
1.25  of  Taq  polymerase.  After  a  ‘hotstart’  (95°C,
5 min),  each  3 min  cycle  consisted  of  1 min  of
denaturation at 95°C, annealing at 55°C, and elonga-
tion at 72°C. Reactions were run for 30 cycles.
Data analysis
Results are expressed as mean ands.e.mean. A com-
parison  of  proliferation  and  chemotaxis  on  dose
response  within  expriments  was  performed  by
ANOVA. Statistical significance was established at the
p<0.05 level. The effects of stimulation/inhibition on
fibroblast migration were evaluated using an analysis
of  variance  and  were  considered  statistically  sig-
nificant at the p<0.05 level.
Results
The effect of glycosaminoglycans on
PDGF-induced fibroblast proliferation
PDGF induced a concentration related cell prolifera-
tion  between  0.1  and  100ng/ml  (Fig.  1).  Heparin
alone (0.1 and 10 U/ml) had no significant effect on
fibroblast proliferation. However, at higher concentra-
tion  heparin  (100 U/ml)  did  cause  a  significant
inhibition  of fibroblast  proliferation  compared  with
the control (Fig. 1, p<0.05).
Heparan sulphate, de-N-suphated heparin and poly-
L-gultamic  acid  (0.1–100 m g/ml)  had  no  significant
effect on cell proliferation.
Accordingly, we examined the effect of heparin (10
and  100 U/ml),  heparan  sulphate,  de-N-sulphated
heparin  and  poly-L-gultamic  acid  (100 m g/ml)  on
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FIG.  1.  Lung  fibroblast  cell  proliferation  due  to  PDGF
(0.1–100ng/ml, open circles)  and to  heparin (0.1–100U/ml,
closed  circles),  heparan  sulphate  (0.1–100 m g/ml,  closed
squares)  de-N-sulphated  heparin  (0.1–100 m g/ml,  open
squares),  and  poly-L-gultamic  acid  (0.1–100 m g/ml,  open
triangles) in the absence of PDGF. The number of cells in the
absence of any drug was 4.3±0.2´ 10
5/ml. Each point presents
the mean ands.e.mean derived from one of three experi-
ments conducted with four replicates for each mean. p<0.05
when compared to control.
FIG. 2. The effect of heparin (10U/ml, open circles; 100U/ml,
closed  circles),  heparan  sulphate  (100 m g/ml,  closed
squares), de-N-sulphated heparin (100 m g/ml, open squares)
and poly-L-gultamic acid (100 m g/ml, open triangles) on lung
fibroblast  cell  division  induced  by  PDGF  (0.1–100ng/ml).
Each point represents the mean ands.e.mean derived from
one of three experiments conducted with four replicates for
each  mean.  p<0.05  compared  with  the  value  for  PDGF
treatment only.PDGF-induced fibroblast proliferation. In the absence
of  glycosaminoglycan,  PDGF-induced  proliferation
was  unaffected  by  any  vehicle  as  shown  by  a
stimulation index of near unity (Fig. 2). Heparin and
de-N-sulphated heparin  significantly  inhibited PDGF
(0.1–100 m g/ml) induced fibroblast proliferation (Fig.
2,  p<0.05).  In  contrast  heparan  sulphate  and  poly-
L-gultamic  acid  had  no  effect  on  PDGF-induced
fibroblast proliferation (Fig. 2). Cell viability assessed
using trypan blue exclusion was found to be greater
than 95% in all experiment.
[H
3]-thymidine incorporation assay
PDGF induced a concentration-related increase in cell
proliferation (142±15% at 1 ng/ml, p<0.05; 224±18%
at  10 ng/ml,  p<0.01)  as  assessed  by  [H3]-thymidine
incorporation. In agreement  with the data obtained
when  assessing  cell  proliferation  by  cell  counting,
heparin  (10  and  100 U/ml)  significantly  inhibited
PDGF-induced  proliferation  (Table  1,  p<0.05)  In
contrast, heparan sulphate (100 m g/ml) had a syner-
gistic effect upon PDGF (10 ng/ml)-induced fibroblast
proliferation (Table 1), but not significantly.
Effect of heparin and heparan sulphate on
chemotaxis
PDGF  induced  a  significant  increase  in  fibroblast
chemotaxis  (control  cell  number=4.2±1.2  vs
PDGF=15.0±4.2, p<0.05).
Heparin inhibited fibroblast chemotaxis in  a con-
centration-dependent manner (Fig. 3). Chemotaxis (%
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Table 1. The effects  of  heparin and heparan sulphate on the incorporation of  [H
3]-thymidine by fibroblasts  treated with
PDGF
Control PDGF (1ng/ml) PDGF (10ng/ml)
Heparin
0 100 142 ± 15 224 ± 18
1U/ml 124 ± 8 136 ± 7 268 ± 18
10U/ml 67.4 ± 4 73 ± 10 202 ± 13
100U/ml 38 ± 3 55 ± 7 81 ± 5
Heparan sulphate
0 100 142 ± 15 224 ± 18
1 m g/ml 114 ± 12 150 ± 26 226 ± 11
10 m g/ml 125 ± 20 137 ± 32 242 ± 18
100 m g/ml 122 ± 17 147 ± 35 244 ± 20
Values represent mean  ±  s.e.mean of the proliferative response above basal levels derived from experiments with six replicates, each mean
represents a significant increase (p<0.05) or significant decrease (p<0.05) in the proliferation of fibroblast when compared with control.
FIG. 3. Inhibitory effects of heparin (U/ml; open circles) and
heparan sulphate (m g/ml; closed  circles)  on PDGF-induced
human  lung  fibroblast  chemotaxis.  The  responses  are
expressed as SI. Each point is the average of triplicate values
from  3  experiments.  Vertical  lines  represents.e.  mean.
p<0.05 when compared with PDGF.
FIG. 4. Effect of anti-MMP1, anti-MMP2, anti-MMP9, TIMP-1
and TIMP-2 on PDGF-induced chemotaxis of fibroblasts. Data
are  shown  as  the  means  ±s.e.mean. Statistical  difference
compared to responses in the presence of the same subtype
of each IgG at a p<0.05 level.of  control)  was  significantly  lower  at  10 U/ml  of
heparin  than  at  any  other  concentration  (p<0.05)
between 0.1–10 U/ml. In contrast, heparan sulphate
(0.1–10 m g/ml)  had  no  significant  effect  on  PDGF-
induced fibroblast chemotaxis.
Anti-hMMP1, anti-hMMP2 and anti-hMMP9 had no
significant  effect  on  fibroblast  chemotaxis,  while
recombinant  hTIMP-1  and  hTIMP-2  inhibited  fibro-
blast chemotaxis significantly (Fig. 4).
Matrix metalloproteinases assay
Fibroblasts  constitutively  express  MMP-1  (control
levels=3.45±0.52  unit/ml)  and  MMP-2/MMP-9  (con-
trol  levels=5.0±0.9  unit/ml)  collagen  activity.  PDGF
significantly  inhibited  fibroblast  collagenase  activity
as assessed by a reduction  in  MMP-1 but not MMP-
2/MMP-9  collagenase  activity  (Fig.  5,  p<0.05). Hep-
arin  but  not  heparan  sulphate  inhibited  fibroblast
MMP-1 and MMP-2/MMP-9 collagenase activity (Fig. 5,
p<0.05).
RT-PCR
PCR  using  specific  oligonucleotide  primer  sets  for
MMP-1, MMP-2 and MMP-9 revealed a single amplifica-
tion product of fibroblast cultured with PDGF. Hep-
arin and heparan sulphate had no inhibitory effect on
the  induction  of  MMP-1,  MMP-2  and  MMP-9  gene
expression (data not shown).
Discussion
We demonstrated the ability of PDGF to modulate the
induction of MMPs and the activity of MMPs in the
present study. Only heparin inhibited fibroblast pro-
liferation,  chemotaxis  and  MMPs  activity.  Our  data
suggests that heparin and related glycosaminoglycans
differentially  regulate  PDGF-induced  lung  fibroblast
proliferation, chemotaxis and MMPs activity and may
play a key role in extracellular matrix remodeling in
inflammatory lung diseases.
Several  previous  studies  suggested  that  intestitial
lung  diseases  are  diffuse  inflammatory  disorders
characterized  by  an  increase  in  the  number  of
inflammatory  cells,  fibroblast  proliferation,  progres-
sive  alteration  of  alveolar-capillary  structures  and
excessive synthesis and deposition of the extracellular
matrix  protein. These  phenomena  are  induced  by
various  growth  factors,  cytokines  and  proteases
produced by infiltrating neutrophils, platelets, macro-
phages, fibroblasts and residential cells. In addition,
biopsy  specimens  from  the  lungs  of  patients  with
pulmonary fibrosis show increased numbers of mast
cells1–3 which have metachromatic granules acting as
growth  factors,  containing  heparin,  histamine  and
proteases. Matrix metalloproteinase also contributes
to  the  role  of  extracellular  matrix  turnover  and
remodeling  in  pulmonary  fibrosis.  However,  less  is
known  about  the  interaction  of  fibroblasts,  growth
factor  and  extracellular  matrix  molecules  in
inflammation.
PDGF  is  one  of  the  most  important  chemo-
attractants  and  mitogens24,25 associated  with  tissue
repair,  a  process  involving  collagen  synthesis  and
remodeling by MMPs. PDGF-like mitogen localized in
the macrophages and epithelial cells of patient with
idiopathic pulmonary fibrosis has been shown to be
an important stimulus for fibroblast proliferation and
collagen production.26 Our present study has demon-
strated the ability of PDGF to induce human fibroblast
chemotaxis using cell migration assay and to induce
proliferation  as  assessed  by  cell  counting  and
H3-thymidine incorporation methods.
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FIG. 5. Bar graph representing the effect of heparin (1U/ml,
cross-hatched  column;  10U/ml,  dark-shaded  column;
100U/ml, light-shaded column), heparan sulphate and PDGF
(1 m g/ml, cross-hatched column; 10 m g/ml, dark-shaded col-
umn; 100 m g/m, light-shaded column): on (a) MMP-1, and (b)
MMP-2/MMP-9  activity  in  lung  fibroblasts.  One  unit  of
collagenase  activity  is  defined  as  the  amount  of  enzyme
degrading 1 m g of collagen per minute. Vertical lines repre-
sents.e.mean from 6 experiments. p<0.05 when compared
with control.Heparin,  a  major  component  of  the  mast  cell
granule  matrix,  is  well  known  as  a  polyanionic
anticoagulant.  Heparin  related  glycosaminoglycans
are abundant components of the extracellular matrix
molecules and are present on cell surfaces in many
tissues. Heparin and related glycosaminoglycans have
been  reported  to  inhibit  bovine  airway  smooth
muscle  division  in  a  concentration-dependent  fash-
ion.16 Similarly, heparin-like glycosaminoglycans have
been reported to inhibit the growth of human arterial
smooth  muscle  cells  in  vitro 15 by  binding  and
inactivating  PDGF  and  also  that  heparan  sulphate
regulated the activity of FGF on fibroblast prolifera-
tion and migration.27 These studies illustrate that the
anti-proliferative activity of the heparin-like molecule
is not limited to airway and vascular smooth muscle
but also to human lung fibroblasts.
It is clear that while low concentrations of heparin
were  ineffective  against  cell  proliferation  and  DNA
synthesis.  Heparin  at  high  concentrations  inhibited
cell  proliferation  and  also  DNA  synthesis  in  fibro-
blasts. This effect is unrelated to a loss in cell viability,
as  assessed by trypan  blue  exclusion.  Furthermore,
the inhibitory effect of heparin was unrelated to its
anionic  charge  since  other  polyanionics  including
poly-L-gultamic  acid  and  heparan  sulphate  had  no
effect on cell proliferation. Moreover, sulphation does
not appear to be necessary for the inhibitory action of
heparin on cell proliferation or DNA synthesis since
de-N-sulphated heparin was as effective as heparin in
this response. It remains unclear whether the effect of
heparin and de-N-sulphated heparin on cell prolifera-
tion is related to the chemical inactivation of PDGF .
Heparin  also  inhibited  fibroblast  migration  in  the
present  study,  whereas  exogenously-administered
heparin  is  known  to  inhibit  cell  migration. These
findings suggest that  endogenously related heparins
may inhibit inflammatory cell infiltration by produc-
ing an anti-inflammatory effect. Indeed, inflammatory
cells are major sources of heparanase which disrupts
glycosaminoglycan linkages and results in the release
of  heparin-like  fragments  from  cellular  heparan
sulphate.28,29
Persistent inflammation in the airway may thereby
influence structural changes including collagen depo-
sition  beneath  the basement  membrane and  airway
smooth  muscle  layer  thickening  as  observed  in
asthma.30–32 Recent  studies  have  indicated  that
matrix metalloproteinases play a role in the degrada-
tion  of  extracellular  matrix  protein  in  tumor  cell
invasion33,34 and neutrophil migration.35 Our present
results show that  human lung fibroblasts in  culture
retain  MMP-1  and  MMP-2/MMP-9  activity.  MMP-
1–interstitial collagenase in fibroblasts–catalyses deg-
radation of collagens, type I, II, III and others. MMP-
2/MMP-9 has the ability to degrade a wide range of
extracellular  matrix  proteins,  including  basement
membrane collagen type IV , fibronectin and gelatin.
Our  results  demonstrate  that  PDGF  inhibits  MMP-1
but  not  MMP-2/MMP-9  activity  in  a  concentration-
dependent  fashion and that  PDGF  differentially  reg-
ulates  MMPs  activity,  fibroblast  proliferation  and
chemotaxis.  We  recommend  that  further  studies
investigate the effects of PDGF  in  the regulation of
MMPs.
Little  is  known  about  the  interaction  between
heparin and MMPs. Our results are significant in the
understanding of fibroblast migration to the basement
membrane  and  extracellular matrix  and  also  of  the
inhibitory effects of heparin on fibroblast migration.
We  observed  that  blocking  the  endogenous  MMPs
with  anti-hMMP1,  anti-hMMP2  and  anti-hMMP9–
which  have  no  effect  on  the  catalytic  site  of  each
MMPs–had  no  effect  on  fibroblast  chemotaxis.  In
contrast, recombinant hTIMP-1 and hTIMP-2 inhibited
fibroblast  chemotaxis  significantly,  which  is  con-
sistent with the notion that fibroblast migration was
thought to be dependent on degradation of collagen.
The ability of heparin to inhibit fibroblast chemotaxis
may account for the inhibitory effects of heparin on
MMPs activity. This hypothesis is further supported by
our result that  heparin  had no  inhibitory  effect on
induction of MMP-1 and MMP-2/MMP-9 mRNA. Fur-
ther  experiments  are  required  to  understand  the
mechanism  by  which  heparin  inhibits  MMPs
activity.
In  conclusion, our results  provide clear  evidence
that  heparin  inhibits  PDGF-induced  human  lung
fibroblast proliferation, chemotaxis and MMPs activ-
ity.  Thus,  endogenously-released  heparin-like  mole-
cules  may  play  an  important  role  in  extracellular
matrix  turnover  and  remodelling  in  inflammatory
lung diseases.
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